Primary cutaneous lymphomas: ESMO Clinical Recommendations for diagnosis, treatment and follow-up

Annals of Oncology

Volumn 18, Issue SUPPL. 2, 2007, Pages

  Dummer, R ^a,b  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

^b ESMO HEAD OFFICE   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORAMBUCIL; CLADRIBINE; CYCLOPHOSPHAMIDE; DENILEUKIN DIFTITOX; DOXORUBICIN; METHOTREXATE; PREDNISONE; PSORALEN; RETINOID; RITUXIMAB; STEROID; VINCRISTINE;

ARTICLE; B CELL LYMPHOMA; CANCER CLASSIFICATION; CANCER GRADING; CANCER INCIDENCE; CANCER STAGING; CANCER SURVIVAL; COMPUTER ASSISTED TOMOGRAPHY; CUTANEOUS T CELL LYMPHOMA; ECHOGRAPHY; ELECTRON THERAPY; EUROPEAN UNION; EVIDENCE BASED MEDICINE; FOLLOW UP; HISTOPATHOLOGY; HUMAN; LOW DRUG DOSE; MYCOSIS FUNGOIDES; PRIORITY JOURNAL; PROGNOSIS; PUNCH BIOPSY; PUVA; RISK ASSESSMENT; SEZARY SYNDROME; SKIN LYMPHOMA; SKIN SURGERY; TREATMENT OUTCOME; TREATMENT PLANNING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; HUMANS; LYMPHOMA, NON-HODGKIN; NEOPLASM STAGING; RISK ASSESSMENT; SKIN NEOPLASMS;

EID: 54349111158     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdm040     Document Type: Article

References (11)

1. Rein Willemze, Elaine S. Jaffe, Günter Burg et al. WHO-EORTC classification for cutaneous lymphomas. Blood 2005; 105 (10): 3768-3785.
2. Grange F, Bekkenk MW, Wechsler J et al. Prognostic factors in primary cutaneous large B-cell lymphomas: A European multicenter study. J Clin Oncol 2001; 19: 3602-3610.
3. Bekkenk MW, Geelen FA, van Voorst Vader PC et al. Primary and secondary cutaneous CD30(+) lymphoproliferative disorders: A report from the Dutch Cutaneous Lymphoma Group on the long-term follow-up data of 219 patients and guidelines for diagnosis and treatment. Blood 2000; 95: 3653-3661.
4. Kaye FJ, Bunn PJ, Steinberg SM et al. A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989; 321: 1784-1790.
5. Stadler R, Otte HG, Luger T et al. Prospective randomized multicenter clinical trial on the use of interferon-2a plus acitretin versus interferon-2a plus PUVA in patients with cutaneous T-cell lymphoma stages I and II. Blood 1998; 92: 3578-3581.
6. Duvic M, Hymes K, Heald P et al. Bexarotene is effective and safe for treatment of refractory advanced-stage cutaneous T-cell lymphoma: multinational phase II-III trial results. J Clin Oncol 2001; 19: 2456-2471.
7. Fierro MT, Quaglino P, Savoia P et al. Systemic polychemotherapy in the treatment of primary cutaneous lymphomas: A clinical follow-up study of 81 patients treated with COP or CHOP. Leuk Lymphoma 1998; 31: 583-588.
8. Olsen E, Duvic M, Frankel A et al. Pivotal phase III trial of two dose levels of denileukin diftitox for the treatment of cutaneous T-cell lymphoma. J Clin Oncol 2001; 19: 376-388.
9. Kuzel TM, Hurria A, Samuelson E et al. Phase II trial of 2-chlorodeoxyadenosine for the treatment of cutaneous T-cell lymphoma. Blood 1996; 87: 906-911.
10. Heinzerling ML, Urbanek M, Funk JO et al. Reduction of tumor burden and stablization of disease by systemic therapy with anti-CD20 antibody (rituximab) in patients with primary cutaneous B-cell lymphomas. Cancer 2000; 89: 1835-1844.
11. Bekkenk MW, Vermeer MH, Geerts ML et al. Treatment of multifocal primary cutaneous B-cell lymphoma: A clinical follow-up study of 29 patients. J Clin Oncol 1999; 17: 2471-2478.